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Abstract The precipitating factors of idiopathic pulmonary ¢brosis (IPF) have not been elucidated.Recently, a novel
DNAvirusnamed TTvirus (TTV) wasdiscoveredin a patientwithpost-transfusionhepatitis of unknown aetiology. TTV
is a circular, single-stranded DNAvirus of 3?8 kB.To evaluate the relationship betweenTTV and IPF, the sera of 33 pa-
tients with IPF were tested for the presence of TTVDNAby semi-nested polymerase chain reaction.TTVDNAwas
detected in 12 (36?4%) IPF patients. The serum lactate dehydrogenase (LDH) level was signi¢cantly higher in the IPF
patientswithTTV than in thosewithout TTV (802+121vs. 530+49 IUl71, P50?05). Six (50%) of12 patients in theTTV
DNA-positive group died during the observation period, while only six (28?6%) of 21patients in theTTVDNA-negative
group died.The 3-year-survivalratewas signi¢cantly lower intheTTVDNA-positive group than intheTTVDNA-nega-
tive group (58?3% vs.95?2%, P50?02).Replicative intermediate forms of TTVDNAwere detected in the lung specimen
fromaTTV-infected IPF patient.TTVinfectionin£uences the disease activityandprognosis of IPF in some cases.Further
studies are required to elucidate the clinical signi¢cance of TTVin IPF.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1151, available online athttp://www.idealibrary.comon
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Idiopathic pulmonary ¢brosis (IPF) is characterizedby ¢-
broproliferation with only minor signs of in£ammation,
and it almost always causes rapid ¢brotic destruction of
the lung (1,2). Regardless of whether treatment is given,
themedian survival is 4^5 years after the onset of symp-
toms (3,4). Although IPF is an interstitial lung disease of
unknown aetiology, the sera of patients with IPF may
contain clues to its aetiology. Rheumatoid factor and/or
antinuclear antibodies are detected in the sera of ap-
proximately 30^50% of IPF patients (5). Furthermore,
since Hamman and Rich (6) ¢rst described interstitial
pneumonitis of unknown origin, and many IPF patients
date the onset of their symptoms to a viral infection or
a‘cold’, it hasbeen suspected that an occultviral infection
is implicated in the pathophysiology of IPF. In fact, many
patients with IPF have a history showing that their dis-
easewas precededby aviral-like illness.Cellular inclusion
bodies suggestive of viral infection have been found in
the lung (alveolar) cells of patients with IPF (7,8). Patients
with IPF may demonstrate persistent activation ofReceived 20 December 2000 and accepted in revised form11June 2001.
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Fax: 81-285-44-3586; E-mail: kokyu2@jichi.ac.jp.macrophages and lymphocytes (9,10), which could be the
natural reservoir for many latent viruses such as cyto-
megalovirus (CMV) (11). Previously, hepatitis C virus
(HCV) and Epstein^Barr virus (EBV) were reported to
be implicated in the aetiology of IPF (12,13). Although no
later study has proven that these viruses can be cultured
from lung specimens of patients with IPF, viruses causing
latent infection canbe considered as possible aetiological
agents of IPF (14).
In1997, a novelDNAviruswas isolated from the serum
of a patient with post-transfusion hepatitis of unknown
aetiology (non-A to G) (15,16) and this virus was named
TT virus (TTV) after the initials of the ¢rst patient in
whom it was discovered.TTV is an unenveloped, single-
stranded, circularDNAviruswith a total genomic length
of approximately 3.8 kB (17,18).TTV has been detected in
the faeces of infected patients (19). It is now known that
TTV is associated with post-transfusion hepatitis in sev-
eral parts of the world.Twelve per cent of Japanese (16),
62% of Brazilian (20), and 7% of Thai blood donors carry
TTV (21). In the U.K., only 1.9% of 1000 blood donors
were found to be infected withTTV (22), while 1% of a
cohort of North American blood donors were found
to be infected (23). TTV infection is apparently
associated with hepatitis B, although it is not associated
with chronic autoimmune hepatitis. Thus, TTV can be
936 RESPIRATORYMEDICINEtransmitted through parenteral routes. However, the
high seroprevalence of TTV among healthy people in
Japan, Brazil and Thailand and the fact that theTTV vir-
aemic load increases with age suggest the existence of
other non-parenteral or community-acquired routes of
transmission, such as the foecal^ oral route. Persistent
TTV infection is postulated to last at least 8 years (24).
TTV shows considerable genomic variability for a
DNAvirus, and at least16 genotypeshavebeen identi¢ed
(25,26).Thegenomic areas that are selected fordesigning
primers for polymerase chain reaction (PCR) ampli¢ca-
tion of TTVDNA, considerably in£uence the rate of de-
tection of TTVDNAby PCR (25,27).Namely, PCRusing
primers based on the sequence of a coding region can
detect a genotype-dependent TTVDNA, but PCRusing
primers based on the sequence of a non-coding region
can detect nearly all genotypes of TTV DNA, resulting
in the detection of TTVDNA in themajority of infected
individuals, irrespective of disease status (28,29).Hence,
the prototype PCRmethod that can detect the fourma-
jor genotypes of TTV,1^4,was used in thepresent study.
TTV may replicate in the liver and in bone marrow
cells, since circular, double-stranded TTV DNA mole-
cules, which are the replicative intermediate form, have
been detected in these organs (30,31). However, the ex-
act range of organ tropism of TTV has yet to be deter-
mined. In the present study,TTVDNAwas detectable in
12 (36?4%) of 33 IPF patients; furthermore, replicative
forms of TTV DNAwere detected in the lung tissue of
a viraemic IPF patient, suggesting the possible associa-
tion between the newly discovered human DNA virus,
TTVand IPF.
METHODS
Patients
Between February1997 and February 2000, 33 patients
with IPF [20 males and 13 females; age, 65?3+10?0 years
(mean+SD), 44^81 years (range)] were admitted to the
Division of PulmonaryMedicine, Jichi Medical School, Ja-
pan, and these patients were enrolled in this study. All
patients ful¢lled the standard clinical criteria for the di-
agnosis of IPF (2,32).The following clinical features were
observed in all 33 patients: (1) inspiratory bibasilar
crackles; (2) progressive pulmonary reticulonodular sha-
dowing predominantly in the basilar and peripheral
zones on chest radiograph; (3) lower lobe pulmonary ¢-
brosis with or without traction bronchiectasis, and low-
er lobe honeycombing without ground glass opacity on
high-resolution computed tomography (HRCT); (4) re-
strictive pattern with reduced di¡using capacity of the
lung for CO (DLCO); (5) no associated infection, neo-
plasm, collagen^vascular disease, systemic vasculitis, ex-
posure to ¢brogenic factors known to be associated
with interstitial lung disease (ILD) (occupational and in-herited history, exposure to birds, drugs), and inherited
diseases known to be associated with ILD/pulmonary ¢-
brosis (e.g. neuro¢bromatosis, Hermansky^Pudlak syn-
drome, metabolic storage diseases). In 20 patients,
surgical lung biopsy (SLB) or transbronchial lung biopsy
(TBLB) was performed, and typical histological features
of usual interstitial pneumonia (UIP) were observed in
these 20 patients. The survival status as of March 2000
was established for each IPF patient based on hospital
clinical records. Survival was calculated based on the
date of onset of symptoms of IPF. The protocols of this
study were approvedby the Committee forHuman Sub-
jects at Jichi Medical School Hospital. Informed written
consentwas obtained from each patient.
Pulmonary function tests
Lung function testswereperformedon all patientswith-
in 6months of the test for detection of TTVDNA in the
patient’s serum.The tests included forced expiratory vo-
lume in 1sec (FEV1), vital capacity (VC), DLCO, DLCO ad-
justed for alveolar volume (DLCO/VA) and the arterial
O2 pressure (PaO2).
Detection of serologicalmarkers
The serum sample taken at admissionwas tested for the
presence of antinuclear antibody (ANA), rheumatoid
factor (RF), hepatitis B surface antigen (HBsAg) [en-
zyme-linked immunosorbent assay (ELISA)] and anti-
body to hepatitis Cvirus (anti-HCV) (second generation
ELISA).The levels of lactate dehydrogenase (LDH),C-re-
active protein (CRP) and KL-6 (33), which is a newuseful
marker of ILD, were also measured to evaluate the dis-
ease activity of IPF.
Detection and genotyping of TTVDNAby
PCR
A portion of each serum sample taken at admission had
been stored at7708C until use. Nucleic acids were ex-
tracted from the serum (50ml) using the High PureViral
Nucleic Acid Kit (Boehringer Mannheim, Mannheim,
Germany) and dissolved in nuclease-free distilled water.
The extractednucleic acids corresponding to 25ml of the
serumwere subjected to PCRusing semi-nestedprimers
and Perkin-Elmer AmpliTaq DNA polymerase (Roche
Molecular Systems, Inc., Branchburg, NJ, U.S.A.) as pre-
viously described (16,19). Brie£y, the primers of the 1st
PCR were NG059 (sense: 5’ -ACA, GAC, AGA, GGA,
GAA, GGC, AAC, ATG-3’) and NG063 (antisense: 5’ -
CTG,GCA,TTT,TAC, CAT,TTC, CAA, AGT,T-3’).The
conditions of the ¢rst PCR were 35 cycles of denatura-
tion at 948C for 30 sec, annealing at 608C for 45 sec and
extension at 728C for 45 sec, followedby a ¢nal extension
TT VIRUS INIPF 937at 728C for 7min. The primers of the second PCR (25
cycles: same conditions as the ¢rst PCR) were NG061
[sense: 5’ -GGC, AAC, ATG, YTR, TGG, ATA, GAC,
TGG-3’ (YTor C, RA or G)] and NG063. The ¢rst
and second PCRs ampli¢ed a 286-bp and 271-bp DNA
fragment, respectively.The ampli¢cation products were
subject to electrophoresis on a 2?5%NuSieve 3:1agarose
gel (FMC BioProducts, Rockland, ME, U.S.A.), stained
with ethidium bromide and observed under ultraviolet
(UV) light.
Typing of TTV into the four major genotypes (1^4)
was performed by PCR with primers speci¢c for each
genotype by the method described previously (34).
Brie£y, using the ampli¢cation productof the ¢rst-round
PCR with primers NG059 and NG063 as a template
(286bp), PCRwas performedwith type-speci¢c primers
in the presence of Perkin^Elmer AmpliTaq Gold (Roche
Molecular Systems, Inc.) for 25 cycles (958C for 30 sec
with an additional 9min in the ¢rst cycle; 588C for
30 sec; 728C for 40 sec, followed by a ¢nal extension at
728C for 7min).The ampli¢cation productwas subjected
to electrophoresis on a 2^4% NuSieve 3:1 agarose gel
(FMCBioProducts) to detectbands compatiblewith gen-
otypes 1, 2, 3 and 4, which were sized at 150, 161, 74 and
195bp, respectively.
Detection of replicating forms of TTVDNA
in lung specimens
Lung tissue (10mg) was obtained during thoracoscopic
biopsy from one IPF patient withTTVDNA in the circu-
lation (patient 9 inTable1).The lung tissue was homoge-
nized, and then incubated in the presence of proteinaseTABLE 1 Pro¢les of TTVDNA-positive patientswith idiopathic
Patient Age/sex TTVDNA
(copiesml71)
TTVgeno-
type
LDH
(IUl71)
K
1 44M 102 2 500
2 63M 104 1+2+3 510
3 65M 101 4 660
4 74M 101 1 1865
5 53M 102 1+2+4 934
6 73F 102 1 551
7 81M 102 3 549
8 69M 101 1 1022
9 66M 103 1 883
10 54M 103 1+4 489
11 81F 102 1 435
12 49M 102 1+2 1226
TTV:TTvirus;LDH: lactate dehydrogenase (normal: 215^410
of predictedvital capacity.
*Duration of survival fromthe onsetofthis disease.Kand sodiumdodecyl sulfate at 378C for14h.Thenucleic
acidswere then extracted andprecipitatedwith ethanol.
The DNAs extracted from the serum and lung tissues
of patient 9 were subjected to electrophoresis on a 1%
(w/v) agarose gel (SeaKem GTG agarose; FMC BioPro-
ducts) in DNase-free electrophoresis bu¡er (pH 8?3)
containing 40mM Tris-acetate and 1mM EDTA (1:10 dilu-
tion of 106TAE bu¡er; Gibco-BRL, Grand Island, NY,
U.S.A.).They were run horizontally for115mm in length
in parallel with a size marker (500-bp DNA ladder; Ta-
KaRa Shuzo Co., Ltd, Shiga, Japan). After electrophor-
esis, the gel was stained with ethidium bromide and the
area corresponding tomolecular sizes1.7^6.8kBwas cut
into 20 gel slices as previously described (30).The DNA
recovered fromeach slice, was subject to PCR ampli¢ca-
tion of TTV DNA with primers NG061 and NG063. To
examine the strandedness of TTV DNA in the serum
and lung tissues, the DNA extracted from each agarose
gel slice was digested with restriction endonuclease
NdeI or S1nuclease (TaKaRa Shuzo), and then ampli¢ed
by PCR. The products were subjected to electro-
phoresis and the ampli¢cation signals were compared
for intensity.
Statistical analysis
The results are presented as mean+standard deviation
(SD).The frequency between groups was compared using
the Mann^Whitney U-test or chi-squared test.The sur-
vival rate between groupswas comparedby the log rank
test. Kaplan^Meier survival curves of those who were
or were not infectedwithTTVDNA,were constructed.pulmonary ¢brosis
L-6 (Ul71) CRP
(mgdl71)
%VC (%) Duration of
survival
(months)*
Prognosis
1650 0?4 53?0 36 Dead
3038 1?6 67?1 4226 Alive
2515 0?5 44?2 19 Dead
1830 14?6 40?7 20 Dead
9837 14?7 73?2 43 Dead
1655 4?8 66?2 4127 Alive
1391 0?3 66?2 35 Dead
7222 9?8 50?0 18 Dead
1401 2?0 102?4 410 Alive
1720 0?2 42?5 484 Alive
354 0?9 82?6 461 Alive
717 27?5 40?3 491 Alive
IUl71);KL-6 (normal: less than 500 Uml71); %VC: percentage
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TTVDNAin the sera of patientswith IPF
The sera of 33 patients with IPF were tested for TTV
DNA by semi-nested PCR. TTV DNA was detected in
12 (36?4%) of the 33 IPF patients. The characteristics of
the 12 TTV DNA-positive patients are shown inTable 1.
The relative titre of TTV DNA in the serum ranged be-
tween101and104 copiesml71.TheTTV in the12 patients
was classi¢ed into the four major genotypes (1, 2, 3 and
4). Of the 12 TTV DNA-positive IPF patients, four pa-
tients had mixed infection of various genotypes of TTV.
Nine patients had TTV genotype1, four had TTV geno-
type 2, twohad TTV genotype 3 and threehad TTVgen-
otype 4.TABLE 2 Comparison of various features between theTTVDN
pathic pulmonary ¢brosis
Feature TTVDNA (+)
(n12)
Age: median, range (years)* 64 (44^81)
Sex (male) 10 (83%)
Durationof illness:median, range
(months){
25 (5^195)
Smokinghabit 8 (67%)
Historyof blood transfusion 1 (8%)
Serologicalmarker
HBsAg 0
Anti-HCV 0
Rheumatoid factor 2 (17%)
Antinuclear antibody 6 (50%)
CRP (mgdl71) 6?4+2?5
KL-6 (Uml71) 2778+818
LDH (IUl71) 802+121
Liver functiontest
AST (IUl71) 42?8+17?4
ALT (IUl71) 64?4+34?3
ALP (IUl71) 207?8+15?3
g-GTP (IUl71) 45?6+7?8
Pulmonary functiontest
VC (l) 1?85+0?16
%VC 60?7+5?6
%DLCO/VA 62?4+8?9
PaO2 (Torr) 63?5+2?8
CRP:C-reactive protein (normal:50?1mgdl71);KL-6 (normal
2157410 IUl71); AST: aspartate aminotransferase (normal:1173
ALP: alkaline phosphatase (normal: 89^285 IUl71); g-GTPg-glu
%VC: percentage of predicted vital capacity; %DLCO/VA: percen
pressure.
*Groupmeanis expressed asmedian andrange.
{Not signi¢cant.
{Duration of survival fromthe onsetof illness.Comparison of theTTVDNA-positive and
TTVDNA-negative IPF patients
TheTTV DNA-positive group included two females and
10 males with a median age of 64 years (range, 44^
81years). The TTV DNA-negative group included 11 fe-
males and10 males with a median age of 66 years (range,
47^78years).The clinical features of the two groups are
summarized and compared inTable 2. No signi¢cant dif-
ferenceswere foundin age, smokinghabit andprevalence
of HBsAg, anti-HCV, rheumatoid factor and antinuclear
antibodies between the two groups. The median dura-
tion of symptoms from onset to diagnosis was similar in
the two groups: 25 months (range, 5^195 months) in the
TTV DNA-positive group and 31months (1^90 months)
in theTTVDNA-negative group.A-positive and -negative groups in the 33 patients with idio-
TTVDNA (7)
(n21)
Di¡erences
66(47^78) NS*
10 (48%) P50?05
31 (1^90) NS
11 (52%) NS
1 (5%) NS
1 (5%) NS
4 (19%) NS
4 (19%) NS
12 (57%) NS
2?7+1?1 NS
1746+215 NS
530+49 P50?05
22?6+3?7 NS
32?9+4?5 NS
216?8+16?9 NS
40?3+7?1 NS
2?26+0?21 NS
79?3+4?6 P50?05
84?0+10?8 NS
71?4+3?0 NS
: less than 500Uml71);LDH: lactate dehydrogenase (normal:
0 IUl71); ALT: alanine aminotransferase (normal: 4^30 IUl71);
tamyl transpeptidase (normal:570 IUl71);VC: vital capacity;
tage of DLCO adjusted for alveolar volume; PaO2: arterial O2
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surement including the levels of KL-6, LDH,CRP, aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), g-glutamyl transpeptidase (g-GTP) and alkaline
phosphatase (ALP), were compared between the two
groups.The serum LDH level of theTTV DNA-positive
patients was signi¢cantly higher than that of the TTV
DNA-negative patients (802+121 vs. 530+49 IUl71,
P50?05). The levels of KL-6, CRP, ASTand ALT tended
to be higher in theTTVDNA-positive group than in the
TTV^DNA-negative group. The results of pulmonary
function tests including VC, %VC, %DLCO/VA, and PaO2
were also compared.The %VC in theTTVDNA-positive
group was signi¢cantly smaller than that in the TTV
DNA-negative group (60?7+5?6% vs. 79?3+4?6%,
P50?05). The levels of %DLCO/VA and PaO2 in theTTV
DNA-positive group were lower than those in the
TTVDNA-negative group, but the di¡erences were not
signi¢cant.
Clinical course and survival status
The survival status of the 33 patients with IPF as of
March 2000was ascertained.The survival rate at 3 years
and at 4 years after the onsetof the illness among the IPF
patients with TTV was signi¢cantly lower than the re-
spective rate among the patients without TTV (3 years,
58?3% or 7/12 vs. 95?2% or 20/21, P0?0082; 4 years,
50?0% or 6/12 vs. 85?7% or18/21,P0?0267) (Table 3). Six
(50%) of the12 patients in theTTV DNA-positive group
died during the observation period, compared with 6
(28?6%) of the 21 patients in the TTV DNA-negative
group; however, the di¡erence was not statistically sig-
ni¢cant. In order to reduce the e¡ect of the di¡erence
in the pulmonary function of these two groups of pa-
tients when comparing the prognosis, we recalculated
the results for patients whose VC was lower than 80%
of the normal level. The results showed that there wasTABLE 3 Comparison of survivalrates betweentheTTV
DNA-positive and -negative groups among the 33 pa-
tientswith idiopathic pulmonary ¢brosis
Feature TTVDNA
(+) (n12)
TTVDNA
(7) (n21)
P-
value
Prognosis
Dead 6 (50?0%) 6 (28?6%) NS
Acute exacerbation 8 (66?7%) 7 (33?3%) NS
Survivalrate
3 years 7 (58?3%) 20 (95?2%) 50?02
4 years 6 (50?0%) 18 (85?7%) 50?05
5 years 6 (50?0%) 16 (76?2%) NS
Home oxygentherapy 7 (58?3%) 6 (28?6%) NSno signi¢cant di¡erence in the survival rate between the
two groups. However, the 3^4-year survival rate of the
TTV-positive group was signi¢cantly lower than that of
theTTV-negative group. Acute exacerbation was more
frequently observed in the TTV DNA-positive group
than in theTTV DNA-negative group, although the dif-
ferencewas not signi¢cant (66?7% vs. 33?3%). In addition,
seven (58?3%) of the12 IPF patientswithTTV had to have
oxygen therapy at home even after leaving the hospital
due to respiratory failure, while six (28?6%) of the 21 pa-
tients without TTV required home oxygen therapy.
Overall, the survival rate from the onset of the illness
was lower in theTTV DNA-positive group than in the
TTV DNA-negative group, although the di¡erence was
not signi¢cant [P0?37 (log rank test)] (Fig.1).
Replicating forms of TTVDNA in the lung
specimens froma patientswith IPF
The DNAs recovered from the serum and from the lung
tissue ofpatient 9were separatedby agarosegel electro-
phoresis. The gel was sliced, and the DNA extracted
from each slice was subjected to PCR for the detection
of TTV DNA.TheTTV DNAs in the serummigrated to
the 2?1^2?5kB region.TheTTVDNAs in the lung sample
migrated to two di¡erent regions (Fig. 2), i.e. the 2?0^
2?4kB region and the 3?5^5?5kB region (speci¢cally the
3?5^4?3 and 4?8^5?5kB regions).
To determine the strandedness of theTTVDNAin the
serum and lung tissues, theTTV DNAs recovered from
the gel slices were digested with S1 nuclease or restric-
tion enzyme NdeI, followed by PCR for detection of
TTV DNA. After treatment with S1 nuclease, theTTV
DNAmolecules recovered from the serum and lung tis-
sues that hadmigrated to the 2?1^2?5kB region, were no
longer ampli¢able, whereas theTTVDNAmolecules re-
covered from the lung samples that hadmigrated to theFIG. 1. Survival curves of patients with idiopathic pulmonary
¢brosis who did or did not haveTTV DNA in the serum.Ka-
plan^Meier survival curves of the IPF patients who did (n12)
ordidnothaveTTVDNA (n21) inthe serum, are shown.
FIG. 2. SeparationofDNAmoleculesextracted fromthe serumandlungspecimenof Patient 9 byelectrophoresisonanagarosegel,
followedbydetectionof TTVDNAingelslices.TheDNAsamplesextracted fromthe serumandlung tissuesofpatient 9 (Table1)were
subjectedto electrophoresisona1% agarosegelinparallelwithamolecular sizemarker [500-bpDNAladder (TaKaRa Shuzo)], andthe
area corresponding to1?7^6?8 kBwas cutinto 20 gel slicesby themethoddescribedpreviously (30,31).DNAwasrecovered fromeach
gel slice and subjected to PCR for the detection of TTVDNA.
940 RESPIRATORYMEDICINE3?5^4?3kB and 4?8^5?5kB regions, could still be ampli-
¢ed. After digestion with NdeI, theTTVDNAs that had
migrated to the 2?1^2?5kB region, could still be ampli-
¢ed. In contrast, the TTV DNAs that had migrated to
the 3?5^4?3kB and 4?8^5?5kB regions, were no longer
ampli¢able after digestion with NdeI. Hence, the TTV
DNAmolecules in the serumwere single-stranded. Both
the single-stranded and double-stranded forms of TTV
DNA were present in the lung samples. The double-
stranded TTV DNA molecules in the lung tissue repre-
sent replicative intermediates.
DISCUSSION
IPF is a clinical syndrome whose aetiology remains un-
clear, and its correct diagnosis and treatment are still a
challenge (1^4).The aetiology of IPF has been proposed
to be an autoimmunemechanism, dust inhalation, ageing,
genetic predisposition and viral infection. In 1944, Ham-
man and Rich (6) ¢rst described a correlation between
IPF and virus infection.Other groups then demonstrated
the inclusion body by histopathological studies (7,8).
Other studies also suggested the involvementof virus in-
fection in the development of IPF (8,11^14). Using PCR
and in situ hybridization, awide range of viruses including
EBV, cytomegalovirus, hepatitis Cvirus and humanT cell
leukemia virus-I, have been speci¢cally found in the pul-
monary alveolar epithelial cells or lymphocytes of IPF pa-
tients, and these viruses may play roles in the
development (¢brosis) of interstitial pneumonitis (13,14).
TTV is a newly discoveredhumanvirus composed of a
circular, single-stranded DNA of approximately 3?8kB(15^18) and it most closely resembles members of the
Circoviridae family (35). TTV is associated with both
transient and persistent infectious status (15), and it has
been suggested that TTVis involved in acute and chronic
liver diseases of unknown aetiology (16,23,36). In addi-
tion, the involvement of TTV in chronic rheumatic ar-
thritis with negative rheumatoid factor and post-
hepatitis aplastic anaemia has been suggested in recent
reports (37,38). However, the precise role of TTV in he-
patic or extrahepatic disease has not yet been de¢ned.
Here, we examined the sera of 33 patients with
chronic IPF for the presence of TTVDNA to investigate
thepossible relationship betweenTTVand IPF, and found
that 36?4% (12/33) of the patients were positive forTTV
DNA.We also investigated a frozen lung tissue specimen
that had been obtained under thoracoscopy from a pa-
tient withTTVDNA in the serum.We found replicative
forms of double-stranded TTV DNA in the lung tissue.
Replicative forms of TTV DNA have also been found in
the liver and bone marrow cells (30,31). These ¢ndings
suggest that TTV replicates in the lung tissues and that
it may be associated with respiratory diseases such as
IPF.
In this report, we showed the di¡erencesbetween the
clinical characteristics of the12 IPF patientswithTTVand
the 21IPF patientswithout TTVinfection.The disease ac-
tivity in the two groups di¡ered.TheTTVDNA-positive
patients had a signi¢cantly higher LDH and tended to
have a higher CRP, KL-6, lower %VC and lower %DLCO
on pulmonary function tests, and lower PaO2 by arterial
blood gasmeasurement.For successful intervention, it is
critical to diagnose IPF promptly and correctly.The activ-
ity of IPF has been evaluated based on data from physio-
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veolar lavage and pulmonary function tests, in addition
to serological tests including CRP, LDH and KL-6 (2,33).
According to the present comparative study,TTV infec-
tion seemed to be associatedwith higher activity of IPF.
In the present study, a di¡erence between the clinical
course of theTTV DNA-positive and TTV DNA-nega-
tive patients was noticed. The survival rates among the
TTVDNA-positive group at 3 years and at 4 years after
the onset of IPF were signi¢cantly lower than those
among the TTV DNA-negative group (P0?0082 and
P0?0267, respectively).Moreover, eight of the12 IPF pa-
tients withTTV showed acute exacerbation and six pa-
tients (50%) died at a mean of 28?5 months after onset.
Seven (58?3%) of the12 TTVDNA-positive patients had
respiratory insu⁄ciency requiring oxygen therapy at
home. In contrast, only six (28?6%) of the 21TTVDNA-
negative patients died during the observation period, at
a mean of 66?7 months after onset. Home oxygen ther-
apy was required in only 28?6%of thepatients in theTTV
DNA-negative group.Themain causes of death in the IPF
patients included exacerbation of respiratory failure,
progression of heart failure and complication of lung can-
cer. Respiratory insu⁄ciency during acute exacerbation
was resistant to intensive intervention such as steroid
pulse therapy. It has been reported that tapering steroid
doses or respiratory infection can induce acute exacer-
bation in IPF (5).However, the actual trigger of acute ex-
acerbation remains to be elucidated, even though
extensive studies on the tissues and £uid from bronch-
oalveolar lavage and thoracoscopic or open lung biopsy
have been done (32).
Based on the observedhigher incidence of early death
due to acute exacerbation and the lower survival rate in
theTTV DNA-positive group, TTV infection is presum-
ably related to the activity and prognosis of IPF. How-
ever, no clear association between human disease and
TTV has been documented. Recently, Christensen et al.
(39) investigated the pathogenic role of TTV in patients
infected with human immunode¢ciency virus (HIV) and
concluded that TTV was suspected to be an opportinis-
tic pathogenwith a signi¢cant e¡ect on HIVdisease pro-
gression, independent of other classic HIV-progression
markers.Our hypothesis presentedhere isbased onpre-
liminary ¢ndings and shouldbe evaluatedin largecohorts
of IPF patients. In addition, howreplicatingTTVinteracts
with the respiratory tract and lung tissues, and how it
in£uences the activity and prognosis of IPF, remain to be
elucidated.
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